Artal Group’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q3 | – | Sell |
-1,032,500
| Closed | -$3.39M | – | 34 |
|
2024
Q2 | $3.39M | Buy |
1,032,500
+672,189
| +187% | +$2.2M | 0.09% | 64 |
|
2024
Q1 | $2.64M | Buy |
+360,311
| New | +$2.64M | 0.07% | 76 |
|
2023
Q2 | – | Sell |
-2,600,000
| Closed | -$14.8M | – | 121 |
|
2023
Q1 | $14.8M | Hold |
2,600,000
| – | – | 0.88% | 29 |
|
2022
Q4 | $26.2M | Hold |
2,600,000
| – | – | 1.46% | 22 |
|
2022
Q3 | $58.3M | Hold |
2,600,000
| – | – | 2.49% | 9 |
|
2022
Q2 | $64.4M | Buy |
2,600,000
+600,000
| +30% | +$14.9M | 3.44% | 9 |
|
2022
Q1 | $77.5M | Buy |
2,000,000
+200,000
| +11% | +$7.75M | 3.25% | 8 |
|
2021
Q4 | $105M | Buy |
1,800,000
+350,000
| +24% | +$20.5M | 2.86% | 8 |
|
2021
Q3 | $85.9M | Buy |
1,450,000
+100,000
| +7% | +$5.93M | 1.92% | 11 |
|
2021
Q2 | $117M | Buy |
1,350,000
+50,000
| +4% | +$4.34M | 2.38% | 9 |
|
2021
Q1 | $107M | Sell |
1,300,000
-100,000
| -7% | -$8.25M | 1.89% | 10 |
|
2020
Q4 | $127M | Sell |
1,400,000
-100,000
| -7% | -$9.09M | 2.73% | 6 |
|
2020
Q3 | $60M | Sell |
1,500,000
-300,000
| -17% | -$12M | 1.46% | 13 |
|
2020
Q2 | $61.8M | Sell |
1,800,000
-300,000
| -14% | -$10.3M | 1.73% | 12 |
|
2020
Q1 | $46.6M | Buy |
2,100,000
+100,000
| +5% | +$2.22M | 1.97% | 12 |
|
2019
Q4 | $39.1M | Hold |
2,000,000
| – | – | 1.51% | 12 |
|
2019
Q3 | $31.1M | Buy |
2,000,000
+500,000
| +33% | +$7.77M | 1.25% | 13 |
|
2019
Q2 | $30.5M | Sell |
1,500,000
-300,000
| -17% | -$6.09M | 1.23% | 17 |
|
2019
Q1 | $31.6M | Sell |
1,800,000
-350,000
| -16% | -$6.15M | 1.29% | 16 |
|
2018
Q4 | $27.6M | Sell |
2,150,000
-40,000
| -2% | -$513K | 1.02% | 15 |
|
2018
Q3 | $35.7M | Buy |
2,190,000
+490,000
| +29% | +$7.98M | 0.93% | 12 |
|
2018
Q2 | $19.3M | Buy |
1,700,000
+850,000
| +100% | +$9.64M | 0.41% | 16 |
|
2018
Q1 | $8.3M | Buy |
+850,000
| New | +$8.3M | 0.1% | 31 |
|